NASDAQ:KNSA - Nasdaq - GB00BRXB0C07 - Common Stock - Currency: USD
19.63
-0.39 (-1.95%)
The current stock price of KNSA is 19.63 USD. In the past month the price decreased by -2%. In the past year, price decreased by -9.71%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.17 | 360.64B | ||
AMGN | AMGEN INC | 15.63 | 166.32B | ||
GILD | GILEAD SCIENCES INC | 24.08 | 138.34B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1660.86 | 123.74B | ||
REGN | REGENERON PHARMACEUTICALS | 15.63 | 77.97B | ||
ARGX | ARGENX SE - ADR | N/A | 38.04B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.11B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.04B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.58B | ||
NTRA | NATERA INC | N/A | 20.91B | ||
BIIB | BIOGEN INC | 8.58 | 20.59B | ||
UTHR | UNITED THERAPEUTICS CORP | 15.73 | 15.99B |
Kiniksa Pharmaceuticals Ltd is a BM-based company operating in Biotechnology industry. Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The firm is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
KINIKSA PHARMACEUTICALS INTE
Clarendon House, 2 Church Street
Hamilton HM11 BM
CEO: Sanj K. Patel
Employees: 297
Company Website: https://www.kiniksa.com/
Investor Relations: https://investors.kiniksa.com/
Phone: 7814399100
The current stock price of KNSA is 19.63 USD. The price decreased by -1.95% in the last trading session.
The exchange symbol of KINIKSA PHARMACEUTICALS INTE is KNSA and it is listed on the Nasdaq exchange.
KNSA stock is listed on the Nasdaq exchange.
12 analysts have analysed KNSA and the average price target is 36.72 USD. This implies a price increase of 87.06% is expected in the next year compared to the current price of 19.63. Check the KINIKSA PHARMACEUTICALS INTE stock analysts ratings, price target forecast and up-and down grades for more detailed information.
KINIKSA PHARMACEUTICALS INTE (KNSA) has a market capitalization of 1.42B USD. This makes KNSA a Small Cap stock.
KINIKSA PHARMACEUTICALS INTE (KNSA) currently has 297 employees.
KINIKSA PHARMACEUTICALS INTE (KNSA) has a support level at 19.94 and a resistance level at 20.03. Check the full technical report for a detailed analysis of KNSA support and resistance levels.
The Revenue of KINIKSA PHARMACEUTICALS INTE (KNSA) is expected to grow by 65.23% in the next year. Check the estimates tab for more information on the KNSA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
KNSA does not pay a dividend.
KINIKSA PHARMACEUTICALS INTE (KNSA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.14).
The outstanding short interest for KINIKSA PHARMACEUTICALS INTE (KNSA) is 4.85% of its float. Check the ownership tab for more information on the KNSA short interest.
ChartMill assigns a technical rating of 1 / 10 to KNSA. When comparing the yearly performance of all stocks, KNSA is a bad performer in the overall market: 66.97% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to KNSA. KNSA has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months KNSA reported a non-GAAP Earnings per Share(EPS) of -0.14. The EPS decreased by -27.27% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -1.63% | ||
ROE | -2.08% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 85% to KNSA. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of -366.33% and a revenue growth 65.23% for KNSA